Relationship between HLA Polymorphisms and Gamma Interferon and Interleukin-10 Cytokine Production in Healthy Individuals after Rubella Vaccination

Inna G. Ovsyannikova,1 Robert M. Jacobson,1,2 Jenna E. Ryan,1 Neelam Dhiman,1 Robert A. Vierkant,3 and Gregory A. Poland1,4,5*

Mayo Vaccine Research Group,1 Department of Pediatric and Adolescent Medicine,2 Division of Biostatistics,3 Program in Translational Immunovirology and Biodefense,4 and Department of Internal Medicine,5 Mayo Clinic, Rochester, Minnesota 55905

Received 5 July 2006/Returned for modification 20 November 2006/Accepted 19 December 2006

We studied the association between HLA alleles and rubella-specific gamma interferon (IFN-γ) (Th1) and interleukin-10 (IL-10) (Th2) cytokine responses among 106 healthy children (ages, 14 to 17 years) previously immunized with two doses of rubella vaccine. Antibody titers and cytokine responses to rubella vaccination were not sex or age dependent. Several class I HLA-A (*0201, *2402, *6801) alleles were significantly associated with rubella vaccine-induced IFN-γ secretion. Several class II HLA-DRB1 (*0101) and HLA-DQB1 (*0501) alleles were also suggestive of an association with IFN-γ secretion. Alleles with potential associations with rubella-specific IL-10 production included HLA-A (*0201, *6801), HLA-B (*4901), and HLA-DRB1 (*1302). The class I A*0201 and A*6801 alleles were associated with both IFN-γ and IL-10 secretion. These tentative associations need to be validated in larger studies with subjects of differing ethnicities. These results provide additional evidence that HLA genes may influence Th1- and Th2-specific cytokine response(s) following rubella immunization, which in turn can influence both cellular and humoral immune responses to rubella vaccination.

Rubella, a viral infection, is still a major health concern in developing countries, with approximately 100,000 cases of congenital rubella syndrome reported worldwide each year (3, 11, 38). Although rare in the United States, the disease exists elsewhere and is imported into developed countries. For this reason, it is important to continue to vaccinate children and women of childbearing age to induce protective immunity and prevent congenital rubella syndrome. The cost of containing and treating rubella cases in developing countries is high (39), and rubella cases continue to be brought into the United States (8, 9, 12).

The vaccine currently used in the United States and in other developed countries consists of the Wistar RA 27/3 strain, attenuated by cold adaptation and serial passage through human diploid cells (37). Immunogenicity trials reveal rates of seroconversion of 92 to 98% (17, 21, 40, 45). Efficacy and immunogenicity studies have shown failure rates of 3 to 14% (5, 16, 20, 40, 43), and borderline or subprotective levels of rubella antibody may exist in percentages ranging from 4 to 23% of vaccinees 6 to 16 years after rubella vaccination (10, 25, 31, 32). The molecular mechanism for this low immune response is unknown; therefore, it is important to understand the immunogenetic mechanisms underlying poor immune response to the vaccine.

Two main CD4 T-helper-cell patterns in response to viral stimulation have been recognized (27, 28). Type 1 helper T cells produce cytokines favoring T-cell-mediated immunity and are classically assessed by measuring gamma interferon (IFN-γ) (or interleukin-2 [IL-2]). Type 2 helper T cells produce cytokines that favor the development of a strong humoral (antibody) immune response and are classically assessed by measuring IL-4 or IL-10. Thus, IFN-γ and IL-10 (or IL-4) can serve as markers to determine whether cellular or humoral immune pathways are predominantly activated, or, alternately, fail to respond to stimulation by vaccination.

Human leukocyte antigen (HLA) genes play an important role in regulating the immune response to viral pathogens via the ability to process and present a repertoire of antigenic peptides to T cells (22, 23, 41). These activated T cells produce patterns of secreted cytokines, thereby being indirectly modulated by HLA molecules to generate a response specific to the stimulatory pathogen (7). Significant differences between these cytokine secretion profiles for peripheral blood mononuclear cells (PBMC) from HLA-B8, DR3-positive individuals and those for HLA-B8, DR3-negative individuals have been observed (7, 24). In fact, HLA-B8, DR3-positive individuals produced levels of IL-2, IL-5, and IFN-γ different from those produced by negative individuals in response to mitogenic PBMC stimulation with phytohemagglutinin (PHA) but produced similar quantities of IL-4, IL-6, and IL-10 (6, 7, 24). This suggests that the HLA-peptide complexes generated in response to vaccination or infection determine the pattern of secretion of cytokines of preferential interest and hence the outcome of the immune response. However, it is not clear whether rubella vaccination has an effect on cytokine production based on the HLA genotype of the host. We hypothesized...
that HLA genes significantly impact the immune response to rubella at the level of cytokine production. To test this hypothesis, we evaluated associations between HLA class I and class II alleles and IFN-γ and IL-10 cytokine production in response to rubella vaccination in healthy subjects.

(This work was presented in part at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 16 to 19 December 2005 [abstract G-843].)

MATERIALS AND METHODS

Study population. We conducted a large, population-based, stratified, random sample study to assess associations between HLA genes and immune responses to measles-mumps-rubella (MMR) vaccine in healthy children and young adults in Olmsted County, MN. The study subjects (n = 106) were randomly selected from a previously recruited and described cohort of 346 children (ages, 12 to 18) enrolled in Minnesota Independent School District 33 (34). Limited PBMC availability did not allow us to study all 346 children. Mayo Clinic’s Institutional Review Board approved the study, and written informed consent and/or assent was obtained from all study participants and their guardians. Each participant had written medical record documentation of receipt of two age-appropriate doses of MMR vaccine (Merck Research Laboratories, West Point, PA). There had been no circulating rubella virus in the community within the participants’ lifetimes, suggesting that immune responses were due to vaccination alone.

Cell isolation and storage. PBMC were purified from heparinized blood by Ficoll-Hypaque (Sigma, St. Louis, MO) density gradient centrifugation as described previously (14). The viability of isolated cells ranged from 95 to 98%, as determined by trypan blue exclusion. The cells were aliquoted and cryopreserved in liquid nitrogen until future use.

Rubella IgG enzyme immunoassay. Whole blood (5 ml) was collected from each subject and allowed to clot, and serum was removed after centrifugation of the sample at 900 × g at room temperature. Aliquots of each serum sample were stored at −80°C. A rubella virus-specific enzyme immunoassay (Enzymost anti-rubella-virus/immunoglobulin G [IgG] enzyme immunoassay; Dade Behring Marburg GmbH, Marburg, Germany) was used to quantify the presence of rubella-virus/immunoglobulin G [IgG] enzyme immunoassay. The samples were run according to the manufacturer’s instructions (BD PharMingen, San Diego, CA).

Enzyme-linked immunosorbent assays (ELISA) for rubella-specific IgG and IFN-γ secretion. Enzyme-linked immunosorbent assays for rubella-specific IgG and IFN-γ secretion were performed in our laboratory as previously described (15, 33), with slight modifications. Thawed PBMC were diluted to a final concentration of 2 × 10^6 cells/ml with RPMI 1640 culture medium containing 25 mM HEPES (Celox Laboratories Inc., St. Paul, MN) supplemented with 100 U/ml penicillin (Sigma, St. Louis, MO), 100 μg/ml streptomycin (Sigma), 1 mM sodium pyruvate (In-vitrogen, Carlsbad, CA), and 0.2% bovine serum albumin (Sigma). PBMC (2 × 10^5/well) from each subject were added in triplicate to flat-bottom tissue culture plates and stimulated either with 35 μM of the Wistar RA 27/3 strain of the rubella virus vaccine (Meruvax, Merck & Co., Inc., West Point, PA) (18) diluted in RPMI 1640 culture medium supplemented with 20% normal human AB serum (Pel-Freeze Biologicals, LLC, Brown Deer, WI) or with RPMI culture medium containing 20% normal human AB serum (Pel-Freeze; negative control) and cultured for 5 days (34). ELISA were performed on cell culture supernatants according to the manufacturer’s instructions (BD PharMingen, San Diego, CA).

The optical density of each plate was measured at 450 nm by use of a microplate reader (Molecular Devices Corporation, Sunnyvale, CA), and the concentration of each cytokine secreted was determined from the standard curve included on each plate. Mean background levels of IFN-γ and IL-10 cytokine production in cultures not stimulated with rubella virus were subtracted from the mean rubella-induced responses to produce corrected secretion values. Negative corrected values indicate that the unstimulated secretion levels were, on average, higher than the stimulated secretion levels.

HLA class I and class II typing. Genomic DNA was extracted from frozen EDTA blood samples by use of a Puregene extraction kit following standard procedures (Gentra Systems Inc., Minneapolis, MN). HLA class I and class II typings were performed as described previously (34, 35). Briefly, the HLA class I A locus was typed using a sCore HLA-A locus-sequencing kit. The HLA-B locus was typed using a reference strand conformation analysis multide B locus kit, and the HLA-Cw locus typing was performed primarily using the Cw high-resolution sequence-specific primer (SSP) UniTray (Pel-Freeze Biologicals, LLC).

Similarly, the HLA class II DRB1 locus was typed using the DRB1 reference strand conformation analysis and SSP UniTray typing kits, while the DBQ1B and DPB1 loci were typed using locus-specific high-resolution SSP UniTray typing kits (Pel-Freeze Biologicals, LLC). Any ambiguities were resolved using additional typing procedures, and the data were analyzed using Match Tools software, as described previously (34, 35). All assays were controlled for reproducibility by repeating every 50th PCR.

Statistical analysis. Our statistical methods are similar to those in previously published reports (34, 35). Briefly, comparisons of immune responses across demographic variables of interest were carried out using Wilcoxon rank sum tests. We assessed pairwise linear associations of different immune response measures by use of Spearman correlation coefficients. Descriptive associations of cytokine response with HLA loci were evaluated on an allelic level, grouped for each locus by allele subtype, and summarized using medians and interquartile ranges. Associations were then more formally evaluated using linear regression analyses. In contrast to the descriptive comparisons, each subject contributed one observation to the regression analysis, with allelic values coded as 0, 1, or 2, according to the number of copies of the allele that a subject carried. Alleles with fewer than five occurrences among all subjects were pooled into a category labeled “other.” Due to data skewness, response values for each regression model were replaced with rank-transformed values. Global differences in cytokine response among all alleles within a given locus were assessed by simultaneously including all but one of the allele variables in a multivariate linear regression model.

Following these global tests, we examined individual allele effects on cytokine response. This latter series of tests was performed in the spirit of Fisher’s protected least significant difference test; individual allele associations were not considered statistically significant in the absence of global significance. Each allele variable was included in a separate linear regression analysis, effectively comparing cytokine response for the allele of interest against those of all other alleles combined.

All global and allelic analyses described above were adjusted for race, gender, age at enrollment, age at first MMR vaccination, and age at second MMR vaccination. All statistical tests were two sided, and all analyses were carried out using the SAS software system (SAS Institute, Inc., Cary, NC).

RESULTS

Study participants. A total of 106 healthy subjects, ranging in age from 14 to 17 years, were recruited into the study. The majority of study participants were white (93.4%). The median ages (first quartile, third quartile) at the first and second immunizations were 15.9 (15.2, 18.3) months and 12.2 (11.7, 12.6) years, respectively. There were a total of 48 (45.3%) females and 58 (54.7%) males in the study. The median value for circulating rubella IgG antibody level was 41.8 IU/ml (Table 1). Both female and male subjects demonstrated similar rubella

| TABLE 1. Immunologic characteristics of study subjects after rubella vaccination |
|---------------------------------|------------------|------------------|------------------|
| Variable                        | No. of subjects | Median (IQR*)    | P value*         |
|---------------------------------|------------------|------------------|------------------|
| Rubella-specific IgG (IU/ml)    |                  |                  |                  |
| Both sexes                       | 106              | 41.8 (23.3, 58.3) | 0.41             |
| Males                           | 58               | 39.21 (19.74, 56.69) |                  |
| Females                         | 48               | 42.41 (23.90, 59.77) |                  |
| Rubella-specific IFN-γ and IL-10 secretion (pg/ml)
| Both sexes                       | 106              | 23.3 (−7.0, 91.3)  | 0.19             |
| Males                           | 58               | 14.60 (−8.35, 76.83) |                  |
| Females                         | 48               | 32.96 (0.98, 132.12) |                  |
| IL-10 secretion for:            |                  |                  |                  |
| Both sexes                       | 106              | 291.0 (197.8, 355.6) | 0.99             |
| Males                           | 58               | 285.71 (202.49, 369.29) |                  |
| Females                         | 48               | 294.90 (192.20, 350.72) |                  |

* IQR, interquartile range (first quartile, third quartile).
* Rubella-stimulated median minus unstimulated median.
* P values compare distributions across gender by use of a Wilcoxon rank sum test.
| Locus | Allele | Allele count | IFN-γ secretion value (pg/ml) | Allele P value<sup>c</sup> |
|-------|--------|--------------|------------------------------|---------------------------|
|       |        |              | Median | First (lower) quartile | Third (upper) quartile    |                        |
| All loci | All alleles | 212 | 23.28 | -6.99 | 91.32 | -- |
| HLA-A |      |              |        |               |                          |                        |
| *0101 | 34   | 23.89 | -0.33 | 89.18 | -- | 0.03 |
| *0201 | 63   | 30.79 | 0.35 | 117.12 | -- |
| *0301 | 35   | 14.04 | -1.58 | 41.86 | -- |
| *1101 | 8    | 18.73 | -13.36 | 39.95 | -- |
| *2402 | 23   | 4.64 | -34.33 | 55.81 | -- | 0.04 |
| *2501 | 5    | 41.86 | -34.05 | 61.23 | -- |
| *5101 | 6    | 13.77 | -20.2 | 64.88 | -- |
| *3201 | 7    | 23.05 | -160.4 | 99.29 | -- |
| *6801 | 13   | 3.03 | -51.54 | 62.78 | 0.03 |
| Other | 18   | 93.78 | 32.48 | 268.31 | -- |
| HLA-B |      |              |        |               |                          |                        |
| *0702 | 23   | 16.33 | -8.02 | 93.78 | -- |
| *0801 | 22   | 11.9 | -28.84 | 53.78 | -- |
| *1302 | 6    | 12.57 | -14.46 | 36.2 | -- |
| *1501 | 20   | 11.13 | -15.6 | 93.23 | -- |
| *1801 | 7    | 49.93 | -34.05 | 410.16 | -- |
| *2705 | 10   | 34.35 | 2.6 | 91.76 | -- |
| *3501 | 9    | 32.49 | 11.43 | 118.02 | -- |
| *3801 | 7    | 199.9 | -53.57 | 287.15 | -- |
| *3901 | 14   | 70.86 | -1.83 | 117.12 | -- |
| *4402 | 25   | 12.36 | -29.33 | 61.23 | -- |
| *4403 | 9    | 36.2 | 11.43 | 93.78 | -- |
| *4901 | 7    | 118.02 | -9.32 | 265.56 | -- |
| *5101 | 6    | 54.91 | -1.58 | 122.61 | -- |
| *5501 | 5    | 13.17 | 1.61 | 93.3 | -- |
| *5701 | 5    | 53.22 | 27.86 | 189.05 | 0.07 |
| Other | 37   | 23.5 | 2.6 | 55.59 | -- |
| HLA-Cw |      |              |        |               |                          |                        |
| *0102 | 9    | 76.34 | 3.04 | 181.36 | -- |
| *0202 | 12   | 41.69 | -4.17 | 105.77 | -- |
| *0303 | 16   | 18.73 | -31.58 | 90.23 | -- |
| *0304 | 21   | 64.88 | 3.03 | 117.12 | 0.07 |
| *0401 | 22   | 28.39 | 3.04 | 99.29 | -- |
| *0501 | 21   | 9.8 | -29.33 | 55.81 | -- |
| *0602 | 16   | 22.09 | 10.72 | 125.91 | -- |
| *0701 | 30   | 12.86 | -24.49 | 84.01 | -- |
| *0702 | 27   | 9.8 | -8.02 | 83.57 | -- |
| *0704 | 5    | 1.61 | -87.18 | 23.5 | -- |
| *1203 | 16   | 51.55 | -13.59 | 277.73 | -- |
| *1601 | 5    | 23.05 | 11.43 | 36.2 | -- |
| Other | 12   | 32.98 | 12.48 | 39.66 | -- |
| HLA-DRB1 |      |              |        |               |                          |                        |
| *0101 | 19   | 91.32 | 14.04 | 214.5 | 0.03 |
| *0301 | 24   | 12.86 | -9.5 | 58.28 | -- |
| *0401 | 23   | 13.17 | -8.35 | 76.34 | -- |
| *0404 | 8    | 15.33 | -8.04 | 47.83 | -- |
| *0701 | 22   | 30.67 | 11.43 | 53.78 | -- |
| *0801 | 6    | 9.29 | -1.58 | 30.79 | -- |
| *0901 | 5    | 61.23 | -29.37 | 76.83 | -- |
| *1101 | 10   | 77.41 | 13.17 | 120.22 | -- |
| *1104 | 5    | 199.9 | 16.33 | 410.16 | -- |
| *1201 | 5    | -8.02 | -8.06 | 37.46 | -- |
| *1301 | 18   | 9.9 | -1.83 | 62.78 | -- |
| *1302 | 11   | 64.88 | -23.15 | 117.12 | -- |
| *1401 | 6    | 69.56 | 23.5 | 118.02 | -- |
| *1501 | 22   | 47.42 | -20.2 | 268.31 | -- |
| Other | 28   | 8.5 | -8.16 | 55.59 | -- |
| HLA-DQB1 |      |              |        |               |                          |                        |
| *0201 | 27   | 12.36 | -4.55 | 53.78 | -- |
| *0301 | 17   | 33.48 | 11.43 | 49.93 | -- |
| *0302 | 45   | 16.33 | -8.02 | 93.3 | -- |
| *0303 | 19   | 15.13 | -8.06 | 61.23 | -- |
| *0304 | 11   | 61.23 | -29.37 | 99.29 | -- |
| *0402 | 7    | 2.6 | -23.9 | 15.98 | -- |

Continued on following page
antibody responses (median values of 42.4 IU/ml versus 39.2 IU/ml, respectively); females demonstrated slightly higher antibody levels than males, but this difference was not statistically significant (P = 0.41). All study subjects were antibody seropositive after receiving two doses of the rubella vaccine. Rubella virus vaccine was able to induce a recall rubella-specific IFN-γ and IL-10 cytokine response from PBMC of previously immunized subjects. Median values (first quartile, third quartile) for rubella-specific IFN-γ and IL-10 cytokines were 23.3 (7.0, 91.3) pg/ml and 291.0 (197.8, 355.6) pg/ml, respectively. Cytokine responses to rubella vaccination were not sex or age dependent (median IFN-γ levels, 33.0 pg/ml for females versus 14.6 pg/ml for males [P = 0.19]; median IL-10 levels, 294.9 pg/ml for females versus 285.7 pg/ml for males [P = 0.99]). Rubella-specific IFN-γ and IL-10 responses were detected in 71% and 99% of subjects, respectively. The linear correlation between rubella-specific IFN-γ and IL-10 secreted cytokines was 0.26 based on rank-transformed data (P = 0.007). Finally, we did not find any correlation between antibody levels to rubella and IFN-γ (r = 0.10, P = 0.32) and IL-10 (r = 0.02, P = 0.86) cytokines.

**Table 2—Continued.**

| Locus       | Allele | Allele count | IFN-γ secretion value (pg/ml) | Allele P value |
|-------------|--------|--------------|------------------------------|----------------|
|             |        | Median       | First (lower) quartile | Third (upper) quartile |
| **HLA-DPB1** |        |              |                             |                |
| *0101       | 17     | 14.04        | –0.33                       | 62.78           |
| *0201       | 21     | 49.93        | 2.6                         | 87.16           |
| *0402       | 16     | 52.76        | 6.77                        | 99.48           |
| *0401       | 91     | 23.17        | –8.35                       | 89.18           |
| *0402       | 29     | 15.17        | 4.64                        | 64.88           |
| *0601       | 5      | 19.23        | 4.64                        | 64.88           |
| Other       | 33     | 23.05        | –1.58                       | 99.29           |

*a* Other includes the following: HLA-A alleles *0102, *0202, *0205, *0206, *0207, *0208, *0209, *0210, *0302, *2301, *2403, *2601, *2608, *2902, *3001, *3002, *3206, *3301, *6601, *6802, *6803, and *6901; HLA-B alleles *0704, *0705, *0706, *0714, *1301, *1401, *1402, *1502, *1503, *1506, *1510, *1516, *1517, *1518, *1522, *1525, *1803, *2702, *3502, *3503, *3504, *3506, *3523, *3701, *3901, *3902, *3906, *4002, *4101, *4201, *4404, *4405, *4501, *4601, *4701, *4803, *5201, *5301, *5601, *5702, *5801, and *7301; HLA-Cw alleles *0302, *0403, *0406, *0604, *0706, *0712, *0801, *1202, *1402, *1502, *1505, *1602, *1604, *1701, *1703, and *1802; HLA-DRB1 alleles *0102, *0103, *0202, *0204, *0205, *0405, *0407, *0408, *0802, *0803, *0804, *1001, *1102, *1103, *1105, *1106, *1111, *1119, *1202, *1208, *1303, *1304, *1305, *1310, *1405, *1406, *1410, *1424, *1502, *1503, *1601, and *1602; HLA-DQB1 alleles *0203, *0304, *0306, *0502, *0601, *0604, *0608, *0609, and *0614; and HLA-DPB1 alleles *0501, *0901, *1101, *1103, *1301, *1401, *1501, *1601, *1701, *1901, *2001, *2011, *2301, *2401, *2601, *3001, *5001, *5101, *6301, and *6601.

b Linear regression analysis was done to study allelic associations. Due to data skewness, median values of 0.03, 0.60, 0.53, 0.42, 0.29, and 0.85, respectively.

The association between class I and class II HLA loci and rubella virus-specific IFN-γ and IL-10 cytokine secretion is shown in Table 2. Global statistical tests revealed significant associations with the HLA-A locus (P = 0.03) but did not reveal a statistically significant association between IFN-γ levels and the HLA-B, HLA-Cw, HLA-DRB1, HLA-DQB1, and HLA-DPB1 loci (P values of 0.60, 0.53, 0.42, 0.29, and 0.85, respectively). When alleles were examined individually, HLA associations with higher rubella-specific IFN-γ responses could be potentially attributed to several HLA alleles, including A*0201 (median, 30.79 pg/ml; P = 0.03), B*5701 (median, 53.22 pg/ml; P = 0.07), Cw*0304 (median, 64.88 pg/ml; P = 0.07), DRB1*0101 (median, 91.32 pg/ml; P = 0.03), and DQB1*0501 (median, 91.54 pg/ml; P = 0.03). Conversely, A*2402 (median, 4.64 pg/ml; P = 0.04) and A*6801 (median, 3.05 pg/ml; P = 0.03) alleles were both associated with lower IFN-γ secretion. When the associations were analyzed at the two-digit specificity level, global tests revealed a significant association between the IFN-γ secretion level in response to rubella antigens and the HLA-DQA1 locus (P = 0.05). In particular, the DQA1*05 allele (median, 89.18 pg/ml; P = 0.02) was significantly associated with increased IFN-γ secretion. The association between class I and class II HLA loci and rubella-specific IL-10 (Th2) cytokine secretion was also examined, and the results are summarized in Table 3. Global tests failed to find a statistically significant association with IL-10 cytokine responses and class I (HLA-A, HLA-B, and HLA-Cw [P values of 0.29, 0.39, and 0.54, respectively]) and class II (HLA-DRB1, HLA-DQB1, and HLA-DPB1 [P values of 0.16, 0.13, and 0.85, respectively]) loci. However, univariate analyses identified potential associations between higher IL-10 responses and alleles A*0201 (median, 335.88 pg/ml; P = 0.004), B*4901 (median, 403.42, P = 0.004), Cw*0102 (median, 374.61; P = 0.06), and DRB1*1002 (median, 344.49 pg/ml; P = 0.03). In addition, we found suggestive associations between lower rubella vaccine-specific IL-10 secretion and the alleles A*6801 (median, 269.18; P = 0.004), Cw*0701 (median, 344.49 pg/ml; P = 0.03), and DRB1*0101 (median, 259.87 pg/ml; P = 0.03). Conversely, A*2402 (median, 4.64 pg/ml; P = 0.04) and A*6801 (median, 3.05 pg/ml; P = 0.03) alleles were both associated with lower IFN-γ secretion. When the associations were analyzed at the two-digit specificity level, global tests revealed a significant association between the IFN-γ secretion level in response to rubella antigens and the HLA-DQA1 locus (P = 0.05). In particular, the DQA1*05 allele (median, 89.18 pg/ml; P = 0.02) was significantly associated with increased IFN-γ secretion.
| Locus | Allele | Allele count | IL-10 secretion value (pg/ml) | Allele P value |
|-------|--------|--------------|-------------------------------|---------------|
|       |        |              | Median | First (lower) quartile | Third (upper) quartile | |
| All loci | All alleles | 212 | 291.04 | 197.84 | 355.59 | |-|
| HLA-A | *0101 | 34 | 282.33 | 196.28 | 392.48 | — |
|       | *0201 | 63 | 335.88 | 224.89 | 377.8 | 0.004 |
|       | *0301 | 35 | 293.53 | 185.92 | 349.71 | — |
|       | *1101 | 8 | 326.36 | 253.49 | 352.29 | — |
|       | *2402 | 23 | 259.87 | 160.9 | 329.16 | — |
|       | *2501 | 5 | 185.92 | 168.34 | 233.72 | — |
|       | *3101 | 6 | 313.37 | 202.49 | 343.33 | — |
|       | *3201 | 7 | 283.32 | 188.33 | 391.53 | — |
|       | *6801 | 13 | 269.18 | 197.84 | 282.97 | 0.004 |
|       | Other | 18 | 300.83 | 275.56 | 338.23 | — |
| HLA-B | *0702 | 23 | 296.25 | 269.18 | 352.08 | — |
|       | *0801 | 22 | 280.36 | 193.36 | 374.61 | — |
|       | *1302 | 6 | 266.83 | 112.96 | 369.29 | — |
|       | *1501 | 20 | 290.22 | 195.6 | 363.29 | — |
|       | *1801 | 7 | 271.53 | 168.34 | 293.79 | — |
|       | *2705 | 10 | 278 | 202.49 | 374.61 | — |
|       | *3501 | 9 | 267.37 | 212.75 | 361.24 | — |
|       | *3801 | 7 | 329.16 | 258.1 | 377.8 | — |
|       | *3001 | 14 | 300.15 | 271.62 | 344.49 | — |
|       | *4402 | 25 | 262.84 | 193.88 | 343.33 | — |
|       | *4403 | 9 | 289.06 | 260.88 | 305.41 | — |
|       | *4901 | 7 | 403.42 | 338.1 | 447.18 | 0.004 |
|       | *5101 | 6 | 338.27 | 305.62 | 392.48 | — |
|       | *5501 | 5 | 278.38 | 193.88 | 283.32 | — |
|       | *5701 | 5 | 282.33 | 167.87 | 403.42 | — |
|       | Other | 37 | 288.09 | 185.92 | 335.88 | 0.06 |
| HLA-Cw | *0102 | 9 | 374.61 | 333.22 | 458.65 | 0.06 |
|       | *0202 | 12 | 242.88 | 178.65 | 305.31 | — |
|       | *0303 | 16 | 288.17 | 195.86 | 363.29 | — |
|       | *0304 | 21 | 304.29 | 271.62 | 350.94 | — |
|       | *0401 | 22 | 309.11 | 212.75 | 391.53 | — |
|       | *0501 | 21 | 262.84 | 196.28 | 343.33 | — |
|       | *0602 | 16 | 310.68 | 212.99 | 411.96 | — |
|       | *0701 | 30 | 288.55 | 212.75 | 401.47 | 0.08 |
|       | *0702 | 27 | 293.79 | 174.02 | 349.71 | — |
|       | *0704 | 5 | 304.29 | 197.84 | 333.82 | — |
|       | *1203 | 16 | 311.35 | 222.01 | 374.4 | — |
|       | *1601 | 5 | 267.37 | 142.21 | 296.25 | — |
|       | Other | 12 | 273.98 | 164.06 | 340.78 | — |
| HLA-DRB1 | *0101 | 19 | 293.02 | 212.75 | 374.61 | — |
|       | *0301 | 24 | 280.36 | 191.94 | 361.73 | — |
|       | *0401 | 23 | 275.56 | 168.34 | 355.59 | — |
|       | *0404 | 8 | 324.95 | 265.11 | 350.72 | — |
|       | *0701 | 22 | 246.8 | 154.81 | 296.25 | 0.07 |
|       | *0801 | 6 | 248.28 | 145.45 | 269.18 | — |
|       | *0901 | 5 | 352.08 | 196.28 | 374.57 | — |
|       | *1101 | 10 | 332.52 | 215.6 | 391.53 | — |
|       | *1104 | 5 | 370.99 | 271.53 | 424.53 | — |
|       | *1201 | 5 | 224.89 | 188.33 | 288.09 | 0.10 |
|       | *1301 | 18 | 284.55 | 193.88 | 329.16 | — |
|       | *1302 | 11 | 344.49 | 282.97 | 429.63 | 0.03 |
|       | *1401 | 6 | 319.05 | 293.79 | 392.48 | — |
|       | *1501 | 22 | 294.78 | 271.53 | 352.08 | — |
|       | Other | 28 | 312.07 | 205.9 | 392.75 | — |
| HLA-DQB1 | *0201 | 27 | 278.38 | 188.33 | 348.85 | — |
|       | *0301 | 17 | 259.87 | 145.45 | 293.79 | 0.06 |
|       | *0302 | 45 | 279.5 | 196.28 | 370.99 | — |
|       | *0302 | 19 | 324.66 | 262.84 | 350.94 | — |
|       | *0303 | 11 | 333.22 | 196.28 | 391.53 | — |

Continued on following page
DISCUSSION

This report provides additional data relevant to the associations between HLA polymorphisms and rubella virus vaccine-specific IFN-γ and IL-10 cytokine immune responses following rubella vaccination in healthy children. We demonstrate that HLA alleles and rubella-specific IFN-γ and IL-10 cytokine immune responses play an important role when evaluating immune responses to rubella vaccination. The present study also revealed that rubella-specific IgG antibody titers and cytokine responses to rubella vaccination were not sex or age dependent.

Little is known about associations between HLA genes and rubella vaccine-induced Th1 and Th2 cytokine production. Early papers suggested that the production of IFN-γ by human peripheral lymphocytes stimulated with rubella virus did not require the addition of macrophages and helper/inducer T cells were the main producers of IFN-γ (29). Others demonstrated the ability of rubella virus to replicate in both unstimulated and PHA-stimulated human lymphocytes as well as in macrophages and lymphocyte subpopulations (44). Recent studies demonstrated transient increases in serum levels of IL-10 in children with acute rubella infection (1) and increased production of anti-inflammatory IL-10 on day 30 after rubella vaccination (42). These changes were accompanied by significant reductions in plasma IFN-γ and a profound decrease in the lymphocyte response to PHA (42).

The outcome of the immune response to rubella is regulated by a number of molecules, including the HLA and cytokine production by T cells. These cytokine secretion profiles can be determined by a number of molecules, including the HLA and cytokine expression by TH1 and TH2 cells (4, 13). The cytokine secretion suggested that IFN-γ plays a key role in T-cell proliferation and differentiation and macrophage activation and is known to be an inducer of HLA molecule surface expression and an enhancer of cell-mediated immunity (19, 36, 46). Likewise, human IL-10 is known to be an important anti-inflammatory cytokine which stimulates growth of B cells and secretion of IgG (4). Functionally, IL-10 inhibits HLA class II and CD80 expression, antigen-presenting cell functions, and cytokine production of Th1 and Th2 cells (4, 13).

Numerous studies have demonstrated HLA regulation of cytokine production and, hence, the type of the immune response in both humans and mice (7). Our previous studies demonstrated associations between rubella humoral and cellular immune responses following rubella vaccination and HLA genes in immune response variation (34, 35). Further, Mitchell et al. (26) demonstrated that certain HLA-DR2 (∗1501, ∗1601) and HLA-DR5 (∗1101/∗1104, ∗1201) alleles may influence susceptibility to the development of joint manifestations after the administration of live attenuated rubella vaccine viruses. However, there have been no studies of HLA class I and class II associations with cytokine outcomes after rubella virus exposure, such as vaccination.

In our study, multivariate linear regression modeling of associations between HLA class I and class II antigen groups and cytokine secretion suggested that IFN-γ secretion was significantly associated with class I HLA-A∗0201, A∗2402, and A∗6801 alleles. In addition, suggestive associations were observed with class I HLA-B∗5701 and HLA-Cw∗0304 alleles and with class II HLA-DRB1∗0101 and HLA-DQβ1∗0501 alleles. We also found associations between specific class I A∗0201, A∗6801, B∗4901, Cw∗0102, and Cw∗0701 alleles and class II DRB1∗0701, DRB1∗1302, and DQβ1∗0202 alleles and IL-10 secretion. These data highlight the critical importance of examining T-cell cytokine responses to rubella virus antigens and the need to define such responses in rubella-immunized individuals.

### TABLE 3—Continued

| Locus | Allele | Allele count | IL-10 secretion value (pg/ml) |
|-------|--------|--------------|-------------------------------|
|       |        | Median        | First (lower) quartile | Third (upper) quartile | Allele P value |
| HLA-DPB1 | *0101 | 17 | 306.87 | 254.02 | 374.61 | — |
|         | *0201 | 21 | 293.79 | 215.6 | 399.09 | — |
|         | *0301 | 16 | 333.22 | 290.94 | 347.1 | — |
|         | *0401 | 91 | 288.09 | 193.36 | 355.59 | — |
|         | *0501 | 26 | 296.14 | 271.53 | 361.24 | — |
|         | *0602 | 16 | 274.17 | 183.98 | 321.83 | — |
|         | Other | 33 | 289.06 | 197.84 | 352.08 | — |

a “Other” includes the following: HLA-A alleles *0102, *0202, *0205, *0206, *0207, *0302, *2301, *2403, *2601, *2608, *2902, *3001, *3002, *3206, *3301, *6601, *6802, *6803, and *6901; HLA-B alleles *0704, *0705, *0706, *0714, *1301, *1401, *1402, *1502, *1503, *1506, *1510, *1516, *1517, *1518, *1522, *1525, *1803, *2702, *3502, *3503, *3504, *3506, *3523, *3701, *3901, *3902, *4002, *4101, *4404, *4405, *4501, *4601, *4701, *4801, *4803, *5201, *5301, *5601, *5702, *5801, *5802, *5803, *5804, *6601, *6801, *6802, *6803, and *6901; HLA-Cw alleles *0302, *0403, *0406, *0604, *0606, *0706, *0710, *0712, *0801, *1202, *1402, *1502, *1505, *1602, *1604, *1701, *1703, *1802, *3502, *3503, *3504, *3508, *3523, *3701, *3901, *3902, *3906, *4002, *4101, *4201, *4404, *4405, *4501, *4601, *4701, *4801, *4803, *5201, *5301, *5601, *5702, *5801, *5802, *6802, and *7301; HLA-Cw alleles *0302, *0403, *0406, *0604, *0606, *0706, *0710, *0712, *0801, *1202, *1402, *1502, *1505, *1602, *1604, *1701, *1703, *1802, *HLA-DRB1 alleles *0102, *0103, *0302, *0402, *0403, *0405, *0407, *0408, *0409, *0410, *0803, *0804, *1001, *1102, *1103, *1105, *1106, *1111, *1119, *1202, *1208, *1303, *1304, *1305, *1310, *1315, *1405, *1406, *1410, *1424, *1502, *1503, *1601, and *1602; HLA-DQβ1 alleles *0203, *0204, *0306, *0502, *0601, *0604, *0608, *0609, and *0614; and HLA-DPB1 alleles *0501, *0901, *1001, *1101, *1301, *1401, *1501, *1601, *1701, *1901, *2001, *2101, *2301, *2401, *2601, *3001, *5001, *5101, *6301, and *6601. 

b Linear regression analysis was done to study allelic associations. Due to data skewness, P values were based in rank-transformed data. Analyses were adjusted for age at blood draw, gender, race, age at first MMR, and age at second MMR. P values of ≤0.05 are shown in bold. —, P values of >0.10 have been omitted. The global P values for HLA-A, HLA-B, HLA-Cw, HLA-DRB1, HLA-DQβ1, and HLA-DPB1 loci were 0.29, 0.39, 0.54, 0.16, 0.13, and 0.85, respectively.
and infected individuals from diverse genetic backgrounds. Importantly, two class I alleles, HLA-A*0201 and A*6801, were associated with both IFN-γ and IL-10 secretion following rubella vaccination. Specifically, A*0201 was associated with higher rubella-specific IFN-γ and IL-10 responses. In contrast, A*6801 was associated with lower levels of rubella-induced IFN-γ and IL-10 production. These findings suggest that specific HLA molecules may significantly influence cytokine responses to antigenic stimulation and hence immune outcomes. Though HLA genes have been associated with cytokine secretion levels, single-nucleotide polymorphisms in either the IFN-γ or IL-10 genes, or cytokine receptor genes, or other genes may also influence immune responses after rubella vaccination.

We found a potential association between rubella-specific IL-10 secretion and the DRB1*1302 allele (P = 0.03); however, the DRB1*1302 allele was not associated with rubella antibody levels in our previous work (34, 35). In this study, rubella antibody levels also lacked any correlation with measures of IL-10 (r = 0.02, P = 0.86) cytokine secretion. Similar disagreement in association between antibody levels to measles virus and IL-4 (r = 0.04, P = 0.45) secretion and measures of CD4 T-cell immunity was found in other studies (15, 30). The complex interplay between genetic HLA polymorphisms, secreted cytokines, and measures of humoral and cellular immune responses to rubella vaccine currently precludes a validated model to explain these associations.

A strength of our study is the stratified random sample of our well-characterized cohort of children used to test our hypothesis. School rosters in Minnesota Independent School District 535 were used as the sampling frame from which an age-stratified random sample of healthy children from all socioeconomic strata was obtained. Also, the humoral and cellular immune responses observed were solely due to vaccination, as these subjects had not encountered the wild-type rubella virus in their lifetimes. There are a few limitations to our study. First, associations with some rare HLA alleles may have been missed due to our modest sample size. Second, due to the number of statistical tests, the possibility of associations by chance alone cannot be dismissed. The fact that we found significant associations with IL-10 secretion and the pooled group of “other” alleles for HLA-B and HLA-DOB1 highlights this possibility. Thus, our findings should be confirmed in large studies with subjects of differing ethnicities.

Our previous work demonstrated that levels of rubella-specific IgG antibody were higher in females than in males (P = 0.02) (34, 35). In the present study, females also demonstrated higher antibody levels than males, but this difference was not statistically significant (P = 0.41). The discrepancy between our gender associations in the original study and in the current study is partially due to less power but also partially due to a smaller effect size: 42.4 IU/ml for females and 39.2 IU/ml for males in the current study, compared to 42.4 IU/ml and 33.9 IU/ml, respectively, in the previous study (34, 35). In the original study, we examined 346 children following two doses of rubella vaccine; in the current study, we examined a group of 106 children after two doses of rubella vaccine. Since our study group was moderately small, it is important that our results be confirmed with a larger study population.

In conclusion, our study results provide data suggesting that certain class I and class II HLA alleles may influence the variability of rubella-induced IFN-γ and IL-10 cytokine immune responses following the administration of live attenuated rubella vaccine viruses. In turn, these Th1- and Th2-like cytokine responses may impact the outcome of both cellular and humoral immune responses to rubella virus vaccine or infection. Further work is needed to better understand the complex interplay between cytokines and the role of HLA gene polymorphisms in the outcome of rubella immunity among populations with various HLA allelic distributions.

ACKNOWLEDGMENTS

We thank the subjects who participated in this study and Carla L. Tentis for editorial assistance. We also thank the technicians and nurses from the Vaccine Research Group who made this study possible.

This work was supported by NIH grants AI 48793 and AI 33144 and Mayo Clinic General Clinical Research Center grant M01 RR00855. G.A.P. chairs a DMSB for clinical trials of new vaccines for Merck, but none of these trials involve rubella vaccines. G.A.P. and R.M.J. have performed Merck-sponsored trials of non-MMR vaccines. All other authors report no potential conflicts of interest.

REFERENCES

1. Akaboshi, I., I. Nagayoshi, M. Omura, and K. Iwaki. 2001. Elevated serum levels of interleukin-10 in children with acute rubella infection. Scand. J. Infect. Dis. 33:462–465.

2. Andrews, N., R. G. Peto, G. Berbers, C. Blondeau, P. Croy, A. Davidkin, P. Farrington, F. Fieslet-Groyne, G. Gabutti, E. Gerike, C. Giordano, L. Hesketh, T. Marzec, P. Morgan, K. Capner, K. Osborne, A. M. Pleisner, M. Raus, A. Tischer, U. Ruden, M. Valle, and E. Miller. 2000. The European sero-epidemiology network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiol. Infect. 125:127–143.

3. Best, J. M., C. Castillo-Solorzano, J. S. Spika, J. Icenogle, J. W. Glasser, N. J. Gay, J. Andrus, and A. M. Arvin. 2005. Reducing the global burden of congenital rubella syndrome: report of the World Health Organization steering committee on research related to measles and rubella vaccines and vaccination, June 2004. J. Infect. Dis. 192:1890–1897.

4. Borish, L. 1998. IL-10: evolving concepts. J. Allergy Clin. Immunol. 101: 293–297.

5. Boullanne, N., G. De Serres, S. Ratnam, B. J. Ward, J. R. Joly, and B. Duval. 1995. Measles, mumps, and rubella antibodies in children 5–6 years after immunization: effect of vaccine type and age at vaccination. Vaccine 13:1611–1616.

6. Candore, G., D. Cigna, F. Gervasi, A. T. Colucci, M. A. Modica, and C. Caruso. 1994. In vitro cytokine production by HLA-B8, DR3 positive subjects. Autoimmunity 18:121–132.

7. Caruso, C., G. Candore, M. A. Modica, C. T. Bonanno, G. Sireci, F. Dieli, L. Andrews, N., R. G. Pebody, G. Berbers, C. Blondeau, P. Crovari, I. Davidkin, P. Farrington, F. Fieslet-Groyne, G. Gabutti, E. Gerike, C. Giordano, L. Hesketh, T. Marzec, P. Morgan, K. Capner, K. Osborne, A. M. Pleisner, M. Raus, A. Tischer, U. Ruden, M. Valle, and E. Miller. 2000. The European sero-epidemiology network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiol. Infect. 125:127–143.

8. Centers for Disease Control and Prevention. 1994. Rubella and congenital rubella syndrome—United States, January 1, 1991–May 7, 1994. Morb. Mortal. Wkly. Rep. 46:1247–1250.

9. Centers for Disease Control and Prevention. 1998. Rubella among crew members of commercial cruise ships—Florida, 1997. Morb. Mortal. Wkly. Rep. 47:391–401.

10. Caruso, C., G. Candore, M. A. Modica, C. T. Bonanno, G. Sireci, F. Dieli, L. Andrews, N., R. G. Pebody, G. Berbers, C. Blondeau, P. Crovari, I. Davidkin, P. Farrington, F. Fieslet-Groyne, G. Gabutti, E. Gerike, C. Giordano, L. Hesketh, T. Marzec, P. Morgan, K. Capner, K. Osborne, A. M. Pleisner, M. Raus, A. Tischer, U. Ruden, M. Valle, and E. Miller. 2000. The European sero-epidemiology network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiol. Infect. 125:127–143.

11. Centers for Disease Control and Prevention. 1994. Rubella and congenital rubella syndrome—United States, January 1, 1991–May 7, 1994. Morb. Mortal. Wkly. Rep. 46:1247–1250.

12. Caruso, C., G. Candore, M. A. Modica, C. T. Bonanno, G. Sireci, F. Dieli, L. Andrews, N., R. G. Pebody, G. Berbers, C. Blondeau, P. Crovari, I. Davidkin, P. Farrington, F. Fieslet-Groyne, G. Gabutti, E. Gerike, C. Giordano, L. Hesketh, T. Marzec, P. Morgan, K. Capner, K. Osborne, A. M. Pleisner, M. Raus, A. Tischer, U. Ruden, M. Valle, and E. Miller. 2000. The European sero-epidemiology network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiol. Infect. 125:127–143.

13. Del Prete, G., M. de Carlí, F. Almerigogna, M. G. Giudizi, R. Biagiotto, and S. Ricci. 1995. Thrombosis of Th1 helper (Th1) and type 1 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J. Immunol. 150:353–360.

14. Dhiman, N., I. G. Osvayannikova, R. M. Jacobson, R. A. Vierkant, S. V. Pankratz, S. J. Jacobsen, and G. A. Poland. 2005. Correlation of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children. Clin. Immunol. 115:154–161.
15. Dhiman, N. I., I. G. Ovsyannikova, J. E. Ryan, R. M. Jacobson, R. A. Vierkant, S. V. Pankratz, S. J. Jacobsen, and G. A. Poland. 2005. Correlations among measles virus-specific antibody, lymphoproliferation and Th1/Th2 cytokine responses following MMR-II vaccination. Clin. Exp. Immunol. 142:498–504.

16. Fogel, A., C. B. Gerichter, B. Barnea, R. Handscher, and E. Heeger. 1978. Response to experimental challenge in persons immunized with different rubella vaccines. J. Pediatr. 92:26–29.

17. Freestone, D. G., M. G. Reynolds, J. A. McKinnon, and J. Prydie. 1975. Vaccination of schoolgirls against rubella. Br. J. Prev. Soc. Med. 29:258–261.

18. Freestone, D. S., G. M. Reynolds, J. A. McKinnon, and J. Prydie. 1975. Vaccination of schoolgirls against rubella. Br. J. Prev. Soc. Med. 29:258–261.

19. Grillner, L. 2000. Interferons: cell signaling, immune modulation, antiviral responses and virus countermeasures. J. Gen. Virol. 81:2341–2364.

20. Greaves, W. L., W. A. Orenstein, A. R. Hinman, and W. S. Nerhusian. 1983. Clinical efficacy of rubella vaccine. Pediatr. Infect. Dis. 2:284–286.

21. Grillner, L. 1975. Neutralizing antibodies after rubella vaccination of newly delivered women: a comparison between three vaccines. Scand. J. Infect. Dis. 7:169–172.

22. Klein, J., and A. Sato. 2000. The HLA system. First of two parts. N. Engl. J. Med. 343:702–709.

23. Klein, J., and A. Sato. 2000. The HLA system. Second of two parts. N. Engl. J. Med. 343:782–786.

24. Liu, D., G. Candore, G. C. Romano, C. D’Anna, F. Gervasi, G. Di Lorenzo, M. A. Modica, M. Potestio, and C. Caruso. 1997. Modification of cytokine patterns in subjects bearing the HLA-DR8, DR3 phenotype: implications for autoimmune immunity. Cytokines Cell. Mol. Ther. 3:217–224.

25. Mitchell, L. A., A. J. Tingle, D. Décarie, and R. Shukin. 1999. Identification of rubella virus T-cell epitopes recognized in anamnestic response to RA27/3 vaccine: associations with boost in neutralizing antibody titer. Vaccine 17:2356–2365.

26. Mitchell, L. A., A. J. Tingle, L. MacWilliam, C. Horne, P. Keown, L. K. Gaur, and G. T. Nepom. 1998. HLA-DR class II associations with rubella vaccine-induced joint manifestations. J. Infect. Dis. 177:5–12.

27. Mosmann, T. R., and R. L. Coffman. 1989. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv. Immunol. 46:111–147.

28. Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145–173.

29. Nakayama, T., T. Urano, M. Osano, M. Nakagawa, N. Maehara, K. Sasaki, and S. Makino. 1988. Production of interferon by human peripheral lymphocytes stimulated with rubella virus. Kitsato Arch. Exp. Med. 41:187–193.

30. Naniche, D., M. Garenne, C. Rae, M. Manchester, R. Buchta, S. K. Brodine, and M. R. Oldstone. 2004. Decrease in measles virus-specific CD4 T cell memory in vaccinated subjects. J. Infect. Dis. 190:1387–1395.

31. Orenstein, W. A., K. Herrmann, P. Albrecht, R. Bernier, P. Holmgren, K. J. Bart, and A. R. Hinman. 1986. Immunity against measles and rubella in Massachusetts schoolchildren. Dev. Biol. Stand. 65:75–83.

32. O’Shea, J. M. Best, J. E. Banatvala, W. C. Marshall, and J. A. Dudzien. 1982. Rubella vaccination: persistence of antibodies for up to 16 years. Br. J. Virol. 28:253–255.

33. Ovsyannikova, I. G., R. M. Jacobson, J. E. Ryan, R. A. Vierkant, V. S. Pankratz, S. J. Jacobsen, and G. A. Poland. 2005. HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine. Immunogenetics 56:796–807.

34. Ovsyannikova, I. G., R. M. Jacobson, R. A. Vierkant, S. J. Jacobsen, and G. A. Poland. 2004. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum. Immunol. 65:1506–1515.

35. Ovsyannikova, I. G., R. M. Jacobson, N. Dhiman, J. E. Ryan, N. A. Pinskey, R. A. Vierkant, and G. A. Poland. 2005. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. G-343.

36. Paludan, S. R. 1998. Interleukin-4 and interferon-gamma: the quintessence of a mutual antagonistic relationship. Scand. J. Immunol. 48:459–468.

37. Perkins, F. T. 1985. Licensed vaccines. Rev. Infect. Dis. 7(Suppl. 1):S73–S76.

38. Plotkin, S. A. 2001. Rubella eradication. Vaccine 19:3311–3319.

39. Plotkin, S. A. 2004. Commentary: congenital rubella syndrome should not be a disease of poor countries. Pediatr. Infect. Dis. J. 23:1123–1124.

40. Plotkin, S. A., J. D. Farquhar, and P. L. Ogra. 1973. Immunologic properties of RA27/3 rubella virus vaccine. JAMA 225:585–590.

41. Poland, G. A., and R. M. Jacobson. 1998. The genetic basis for variation in antibody response to vaccines. Curr. Opin. Pediatr. 10:208–215.

42. Pukhalsky, A. L., G. V. Shmarina, M. S. Bliacher, I. M. Fedorova, A. P. Toptygina, J. J. Fisenko, and V. A. Alioshkin. 2003. Cytokine profile after rubella vaccine inoculation: evidence of the immunosuppressive effect of vaccination. Mediat. Inflamm. 12:203–207.

43. Reef, S. E., T. K. Frey, K. Theall, E. Abernathy, C. L. Burnett, J. Icenogle, M. M. McCauley, and M. Wharton. 2002. The changing epidemiology of rubella in the 1990s: on the verge of elimination and new challenges for control and prevention. JAMA 287:464–472.

44. van der Logt, J. T., A. M. van Loon, and J. van der Veen. 2002. The changing epidemiology of rubella in the 1990s: on the verge of elimination and new challenges for control and prevention. JAMA 287:464–472.

45. van der Logt, J. T., A. M. van Loon, and J. van der Veen. 2002. The changing epidemiology of rubella in the 1990s: on the verge of elimination and new challenges for control and prevention. JAMA 287:464–472.

46. Vieux, B. E., V. M. Villarejos, E. B. Klein, E. B. Buynak, A. A. McLean, and M. R. Hilleman. 1980. Clinical and laboratory studies of live attenuated RA 27/3 and HPV 77-DE rubella virus vaccines. Proc. Soc. Exp. Biol. Med. 165:44–49.

47. Young, H. A., and K. J. Hardy. 1990. Interferon-gamma: producer cells, activation stimuli, and molecular genetic regulation. Pharmacol. Ther. 45:137–151.